Patents Examined by James H. Alstrum-Acevedo
  • Patent number: 11149071
    Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 19, 2021
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventors: Huashun Li, Baoyong Ren, Peng Liu
  • Patent number: 11149078
    Abstract: The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 19, 2021
    Assignee: Amgen Inc.
    Inventors: Jason C. O'Neill, Randal R. Ketchem, Taeweon Lee, Vishnu Chintalgattu, Jennitte Leann Stevens
  • Patent number: 11149061
    Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: October 19, 2021
    Assignees: The Board of Trustees of the California State University, California State University, Los Angeles
    Inventor: Xin Wen
  • Patent number: 11150251
    Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 19, 2021
    Assignees: Clemson University Research Foundation, MUSC Foundation for Research Development
    Inventors: Ying Mei, Jia Jia, Chung-Jen James Chou
  • Patent number: 11141466
    Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 12, 2021
    Assignee: CSL Behring Lengnau AG
    Inventors: Anne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
  • Patent number: 11124542
    Abstract: Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1: R1-Nle4-c[Xaa5-Yaa6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Zaa10]-R2. R1 can be an acetyl, a glycosylated amino acid, —CO—(CH2)nCH3, or —CO—(CH2)nCF3 with n ranging from 1 to 6. R2 can be an —CONH2, —COOH, or —CH2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: September 21, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Victor J. Hruby, Minying Cai
  • Patent number: 11116868
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 14, 2021
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 11116816
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 14, 2021
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 11117930
    Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 14, 2021
    Assignee: ADRX, INC.
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
  • Patent number: 11110152
    Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 7, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Julie Ledford, Monica Kraft
  • Patent number: 11111278
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 7, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
  • Patent number: 11111272
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 7, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • Patent number: 11103561
    Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 31, 2021
    Assignee: Hamlet Pharma AB
    Inventors: Catharina Svanborg, Manoj Puthia, Chin Shing Ho
  • Patent number: 11103557
    Abstract: The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: August 31, 2021
    Assignee: ANYGEN Co., Ltd.
    Inventors: San Ho Kim, Seon Myung Kim, Moon Young Park
  • Patent number: 11103549
    Abstract: Provided are methods for prophylaxis and/or therapy for Phelan-McDermid Syndrome (PMS) and autism spectrum disorder (ASD). The methods involve administering a histone methyltransferase (HMT) inhibitor, a histone deacetylase (HDAC) inhibitor, or a combination thereof, such that one or more symptoms of the PMS and/or the AMD are reduced.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 31, 2021
    Assignee: ASDDR, LLC
    Inventor: Zhen Yan
  • Patent number: 11098104
    Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 24, 2021
    Assignee: BEIJING PROTGEN LTD.
    Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
  • Patent number: 11098097
    Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Binoy Appukuttan, Trevor McFarland
  • Patent number: 11096982
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: August 24, 2021
    Assignee: GENENTECH, INC.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Patent number: 11098078
    Abstract: The present invention has an object of providing a peptide synthesis method using a carrier capable of reversibly repeating the dissolved state and the insolubilized state, wherein the problem of an amino acid active species existing in the reaction system in de-protection reaction can be easily solved. The present invention provides a peptide synthesis method comprising the following steps: a step of condensing an N-Fmoc protected amino acid with a peptide having a C-terminal protected with a carrier which is crystallized according to a change of a composition of a dissolving solvent, in the presence of a condensing agent, to obtain an N-Fmoc-C-carrier protected peptide, a step of adding an alkylamine having 1 to 14 carbon atoms or hydroxyl amine to the reaction system, a step of de-protecting the N-terminal, and a step of changing the composition of the solvent dissolving the C-carrier protected peptide, to crystallize and separate the peptide.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: August 24, 2021
    Assignee: JITSUBO Co., Ltd.
    Inventors: Yusuke Kono, Hideaki Suzuki, Susumu Muto
  • Patent number: 11091771
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: August 17, 2021
    Inventors: Ruth Cong, Jingtong Hou, Zhenglin Hou, Phillip A. Patten, Takashi Yamamoto